DEF: Acurx Seeks Shareholder Approval for Capital Raise

Acurx Pharmaceuticals, Inc. is seeking stockholder approval for a significant common stock issuance related to a recent financing and an increase in authorized shares to support future corporate actions.

Summary

• A special meeting of stockholders is scheduled for September 16, 2025, at 11:00 am Eastern Time, to be held virtually.
• Stockholders will vote on three proposals: (i) approval of the issuance of shares underlying Series G-2 warrants to comply with Nasdaq Listing Rule 5635(d), (ii) approval of an amendment to the Certificate of Incorporation to increase authorized common stock from 200,000,000 to 250,000,000 shares, and (iii) approval of an adjournment of the meeting if necessary to solicit additional proxies.
• The Issuance Proposal relates to a warrant inducement agreement dated June 17, 2025, where a holder exercised 222,272 existing warrants for cash at a reduced price of $12.00 per share, in exchange for Series G-1 warrants (up to 311,180 shares) and Series G-2 warrants (up to 133,363 shares), each exercisable at $8.50 per share.
• This financing transaction yielded gross proceeds of approximately $2.67 million.
• As of March 31, 2025, cash was approximately $4.6 million.
• A one-for-twenty reverse stock split of common stock became effective on August 4, 2025.
• As of July 23, 2025, there were 1,538,227 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 6

Explanation: The filing outlines necessary corporate actions to secure future financing and operational flexibility, addressing immediate cash needs and preparing for future growth, despite potential dilution for existing shareholders. It represents a proactive step to strengthen the company's financial position.

Positives

• A financing transaction yielded approximately $2.67 million in gross proceeds, improving the capital position.
• Proceeds from the financing and potential future exercise of Series G-1 and G-2 warrants will provide financing for working capital and general corporate purposes.
• The Board believes the terms of the Series G-1 and G-2 warrants are reasonable given market conditions and the financing transaction's size and type.
• Increasing authorized shares provides flexibility for future corporate actions, including financings, investment opportunities, stock splits, or dividends, avoiding repeated amendments and associated delays/expenses.

Negatives

• Approval of the Issuance Proposal will result in future dilution for existing stockholders upon exercise of the Series G-2 warrants.
• The sale of shares underlying Series G-2 warrants into the public market could materially and adversely affect the market price of common stock.
• If the Issuance Proposal is not approved, the company may be required to pay substantial cash amounts to Series G-2 warrant holders, for which it does not anticipate having sufficient funds.
• Failure to obtain stockholder approval means the Series G-2 warrants would not be exercisable and would have no value.
• If stockholder approval is not obtained, the company is required to call a meeting every 90 days thereafter to seek approval, diverting substantial time and effort from the Board and management.

Risks

• Dilution of existing stockholder ownership interests in the future to the extent shares are issued upon exercise of Series G-2 warrants.
• Potential material adverse effect on the market price of common stock due to the sale of shares underlying Series G-2 warrants into the public market.
• Inability to issue sufficient shares upon exercise of Series G-2 warrants if stockholder approval is not obtained, potentially requiring substantial cash payments that the company may not have.
• Series G-2 warrants would have no value if stockholder approval is not obtained.
• The increase in the number of issued shares of common stock in connection with the financing may have an incidental anti-takeover effect.
• Future issuances of securities may cause a significant reduction in the percentage interests of current stockholders in voting power, liquidation value, book and market value, and future earnings.

Future Outlook

The company intends to use proceeds from the recent financing and potential future warrant exercises for general corporate purposes and working capital. The proposed increase in authorized shares is intended to provide flexibility for future financings, investment opportunities, stock splits, or dividends, avoiding the need for repeated stockholder approvals. The Board reserves the right to abandon the authorized share increase even if approved by stockholders.

Management Comments

• "We believe that the Financing, which yielded gross proceeds of approximately $2.67 million, were necessary in light of the Company’s cash and funding requirements at the time."
• "We also believe that the terms of the series G-1 warrants and the series G-2 warrants are reasonable in light of market conditions and the size and type of the financing transaction."
• "Our Board believes it continues to be in our best interest to have sufficient additional authorized but unissued shares of common stock available in order to provide flexibility for corporate action in the future."
• "Management believes that the availability of additional authorized shares for issuance from time to time in our Board’s discretion in connection with future financings, investment opportunities, stock splits or dividends or for other corporate purposes is desirable in order to avoid repeated separate amendments to our Certificate of Incorporation and the delay and expense incurred in holding special meetings of the stockholders to approve such amendments."

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution of ownership interests, voting power, liquidation value, book and market value, and future earnings due to future share issuances. Potential adverse effect on market price of common stock.

Next Steps

• Hold a special meeting of stockholders on September 16, 2025, to vote on the proposed corporate actions.
• If the Issuance Proposal is not approved, the company will be required to call a meeting every 90 days thereafter to seek stockholder approval until the Series G-2 warrants are no longer outstanding.
• Publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the special meeting.

Key Dates

Keywords

Acurx Pharmaceuticals, ACXP, SEC Filing, Proxy Statement, DEF 14A, Stockholder Meeting, Nasdaq Listing Rule 5635(d), Warrant Inducement Agreement, Series G-2 Warrants, Authorized Share Increase, Reverse Stock Split, Capital Raise, Dilution, Corporate Governance